Unravelling the role of individual components in pBAE/polynucleotide polyplexes in the synthesis of tailored carriers for specific applications: on the road to rational formulations.
Journal
Nanoscale advances
ISSN: 2516-0230
Titre abrégé: Nanoscale Adv
Pays: England
ID NLM: 101738708
Informations de publication
Date de publication:
14 Mar 2023
14 Mar 2023
Historique:
received:
12
11
2022
accepted:
03
02
2023
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Oligopeptide end-modified poly(β-amino ester)s (OM-pBAEs) offer a means for the effective implementation of gene therapeutics in the near future. A fine-tuning of OM-pBAEs to meet application requirements is achieved by the proportional balance of oligopeptides used and provide gene carriers with high transfection efficacy, low toxicity, precise targeting, biocompatibility, and biodegradability. Understanding the influence and conformation of each building block at molecular and biological levels is therefore pivotal for further development and improvement of these gene carriers. Herein, we unmask the role of individual OM-pBAE components and their conformation in OM-pBAE/polynucleotide nanoparticles using a combination of fluorescence resonance energy transfer, enhanced darkfield spectral microscopy, atomic force microscopy, and microscale thermophoresis. We found that modifying the pBAE backbone with three end-terminal amino acids produces unique mechanical and physical properties for each combination. Higher adhesion properties are seen with arginine and lysine-based hybrid nanoparticles, while histidine provides an advantage in terms of construct stability. Our results shed light on the high potential of OM-pBAEs as gene delivery vehicles and provide insights into the influence of the nature of surface charges and the chemical nature of the pBAE modifications on their paths towards endocytosis, endosomal escape, and transfection.
Identifiants
pubmed: 36926558
doi: 10.1039/d2na00800a
pii: d2na00800a
pmc: PMC10012844
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1611-1623Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Expert Opin Drug Deliv. 2020 Oct;17(10):1395-1410
pubmed: 32700581
Front Bioeng Biotechnol. 2020 May 21;8:474
pubmed: 32509754
Cardiovasc Eng Technol. 2021 Feb;12(1):114-125
pubmed: 33474643
Adv Healthc Mater. 2018 Sep;7(17):e1800335
pubmed: 29923337
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Phys Chem B. 2009 Dec 10;113(49):16046-58
pubmed: 19904910
Acta Biomater. 2014 May;10(5):2147-58
pubmed: 24406199
PLoS One. 2012;7(5):e37543
pubmed: 22629417
Polymers (Basel). 2020 Dec 01;12(12):
pubmed: 33271770
Signal Transduct Target Ther. 2019 Aug 30;4:33
pubmed: 31637012
Nat Rev Genet. 2011 May;12(5):316-28
pubmed: 21468099
J Control Release. 2019 Sep 28;310:155-187
pubmed: 31454533
Expert Opin Drug Deliv. 2018 Dec;15(12):1211-1221
pubmed: 30417712
Nanoscale. 2019 Oct 3;11(38):17869-17877
pubmed: 31552987
Adv Healthc Mater. 2019 Jan;8(2):e1801359
pubmed: 30549448
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Clin Microbiol Rev. 1998 Jan;11(1):42-56
pubmed: 9457428
Science. 2021 Oct 22;374(6566):eabj9853
pubmed: 34519540
Rev Sci Instrum. 2007 Jan;78(1):013705
pubmed: 17503926
Adv Drug Deliv Rev. 2021 Oct;177:113807
pubmed: 34023331
Acta Biomater. 2015 Jul;20:82-93
pubmed: 25839122
Nature. 2021 Feb;590(7844):E17
pubmed: 33469214
J Clin Diagn Res. 2015 Jan;9(1):GE01-6
pubmed: 25738007
J Vis Exp. 2021 Aug 13;(174):
pubmed: 34459811
Bioconjug Chem. 2007 Nov-Dec;18(6):1887-96
pubmed: 17929884
Gene Ther. 2003 Mar;10(6):453-8
pubmed: 12621449
Mol Ther. 2012 Oct;20(10):1831-2
pubmed: 23023051
ChemMedChem. 2022 Jul 5;17(13):e202100633
pubmed: 35212466
Nat Rev Methods Primers. 2022;2:
pubmed: 35480987